SCHEMBL20022781

SCHEMBL20022781

O=C1C=C(c2ncco2)CN(CC(=O)c2ccccc2)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.42
KDM4E B2RXH2 1/20 0.42
TP53 P04637 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ALDH1A1 P00352 1/20 0.39
CARM1 Q86X55 1/20 0.36
SMO Q99835 1/20 0.36
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
FAAH O00519 1/20 0.35
HPGDS O60760 1/20 0.35
POLB P06746 1/20 0.34
KMT2A Q03164 1/20 0.34
HTR1A P08908 1/20 0.34
GSK3A P49840 1/20 0.34
GSK3B P49841 1/20 0.34
SLC6A4 P31645 1/20 0.34
SLC6A3 Q01959 1/20 0.34
CA12 O43570 1/20 0.34
CA9 Q16790 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18209824 0.81 ALDH1A1 (0.40) SMN1; SMN2TP53ALDH1A1RAB9AFAAH
SCHEMBL20022782 0.80 ALDH1A1 (0.37) SMN1; SMN2KDM4ETP53L3MBTL1ALDH1A1
SCHEMBL20028325 0.77 SMO (0.36) SMOFAAHHPGDSKMT2A
SCHEMBL20022788 0.74 ALDH1A1 (0.39) SMN1; SMN2KDM4ETP53L3MBTL1ALDH1A1
SCHEMBL18209719 0.72 FAAH (0.47) SMN1; SMN2NPC1RAB9AFAAHKMT2A
SCHEMBL20022779 0.71 SMO (0.32) SMOFAAHKMT2A
SCHEMBL20022797 0.70 ALDH1A1 (0.39) SMN1; SMN2ALDH1A1CARM1RAB9AKMT2A
SCHEMBL15164429 0.69 ALDH1A1 (0.57) SMN1; SMN2KDM4ETP53L3MBTL1ALDH1A1
SCHEMBL30546565 0.66 ALDH1A1 (0.57) SMN1; SMN2KDM4EALDH1A1CARM1RAB9A
SCHEMBL4875267 0.64 ALDH1A1 (0.79) SMN1; SMN2KDM4EALDH1A1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180093985-A1 Heterocyclic Compounds and Their Use in Preventing or Treating Bacterial Infections MUTABILIS (FR) 2018-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180093985-A1 Heterocyclic Compounds and Their Use in Preventing or Treating Bacterial Infections NQO1, PEPD, LCT SMN1; SMN2 3965/4885KDM4E 3033/4885TP53 3164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.